Search results for "CIRRHOSIS"

showing 10 items of 964 documents

Avoiding Pitfalls in the Interpretation of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging

2016

Gadoxetic acid is extensively used in the following 3 main clinical situations: characterization of small nodules in patients with cirrhosis, preoperative staging of liver metastases, and characterization of incidentally discovered focal liver lesions. Owing to the rapid entry of gadoxetic acid into hepatocytes, the traditional features of liver tumors are modified on magnetic resonance (MR) imaging, especially during delayed phase sequences. Thus, although the added value of gadoxetic acid for the detection and characterization of focal liver lesions is now clear, its unique pharmacokinetics as well as the presence of mimicking and atypical lesions may lead to misdiagnoses. The goal of thi…

Gadolinium DTPAmedicine.medical_specialtyGadoxetic acidRadiology Nuclear Medicine and ImagingCirrhosisContrast Mediaddc:616.0757Sensitivity and Specificity030218 nuclear medicine & medical imagingMagnetic Resonance Imaging/methods03 medical and health sciences0302 clinical medicinePreoperative stagingGadolinium DTPAImage Interpretation Computer-AssistedmedicineHumansIn patientmedicine.diagnostic_testbusiness.industryLiver DiseasesLiver DiseaseImage Interpretation Computer-Assisted/methodsMagnetic resonance imagingDelayed phasemedicine.diseaseMr imagingMagnetic Resonance ImagingLiver Diseases/diagnostic imaging030211 gastroenterology & hepatologyRadiologyNuclear medicinebusinessmedicine.drugHuman
researchProduct

Prevention of Upper Gastrointestinal Bleeding in Cirrhotic Patients

1987

The prevalence of varices in patients with cirrhosis is stated to be about 50% and the risk of variceal bleeding 40% with mortality ranging from 30% to 60%. Differences may be due to patient selection and diagnostic criteria. The death risk of first bleeding seems to be higher than that of subsequent episodes (Christensen et al. 1981; D’Amico et al. 1986), indicating that the first bleeding episode causes a selection.

Gastrointestinal bleedingmedicine.medical_specialtyVariceal bleedingCirrhosisbusiness.industrymedicine.diseaseGastroenterologyEsophageal varicesInternal medicinemedicinePortal hypertensionIn patientUpper gastrointestinal bleedingbusinessVarices
researchProduct

TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis.

1999

Transforming growth factor-beta1 (TGF-beta1) is a powerful stimulus for collagen formation in vitro. To determine the in vivo effects of TGF-beta1 on liver fibrogenesis, we generated transgenic mice overexpressing a fusion gene [C-reactive protein (CRP)/TGF-beta1] consisting of the cDNA coding for an activated form of TGF-beta1 under the control of the regulatory elements of the inducible human CRP gene promoter. Two transgenic lines were generated with liver-specific overexpression of mature TGF-beta1. After induction of the acute phase response (15 h) with lipopolysaccharide (100 microgram ip), plasma TGF-beta1 levels reached600 ng/ml in transgenic animals, which is100 times above normal …

Genetically modified mouseLipopolysaccharidesmedicine.medical_specialtyTranscription GeneticPhysiologyTransgeneRecombinant Fusion ProteinsMice TransgenicBiologyRegulatory Sequences Nucleic AcidLiver Cirrhosis ExperimentalMiceDownregulation and upregulationFibrosisIn vivoTransforming Growth Factor betaPhysiology (medical)Internal medicinemedicineAnimalsHumansRNA MessengerPromoter Regions GeneticRegulation of gene expressionHepatologyGastroenterologymedicine.diseaseMolecular biologyImmunohistochemistryEndocrinologymedicine.anatomical_structureC-Reactive ProteinGene Expression RegulationLiverHepatocyteHepatic stellate cellCollagenProcollagen
researchProduct

Spontaneous hepatic fibrosis in transgenic mice overexpressing PDGF-A.

2008

Platelet derived growth factor (PDGF) plays a central role in repair mechanisms after acute and chronic tissue damage. To further evaluate the role of PDGF-A in liver fibrogenesis in vivo, we generated transgenic mice with hepatocyte-specific overexpression of PDGF-A using the CRP-gene promoter. Transgenic but not wildtype mice showed expression of PDGF-A mRNA in the liver. Hepatic PDGF-A overexpression was accompanied by a significant increase in hepatic procollagen III mRNA expression as well as TGF-beta1 expression. Liver histology showed increased deposition of extracellular matrix in transgenic but not in wildtype mice. PDGF-A-transgenic mice showed positive sinusoidal staining for alp…

Genetically modified mouseLiver CirrhosisPlatelet-derived growth factorTransgeneGene ExpressionMice TransgenicTransforming Growth Factor beta1chemistry.chemical_compoundMiceFibrosisGeneticsmedicineAnimalsHumansRNA MessengerPlatelet-Derived Growth FactorbiologyGeneral Medicinemedicine.diseaseMolecular biologyRecombinant ProteinsC-Reactive ProteinCollagen Type IIIchemistryLiverHepatic stellate cellbiology.proteinHepatic fibrosisTyrosine kinasePlatelet-derived growth factor receptorSignal TransductionGene
researchProduct

Sex difference in the interaction of alcohol intake, hepatitis B virus, and hepatitis C virus on the risk of cirrhosis

2017

Background The joint effect of the interaction of alcohol intake, hepatitis B virus (HBV) and hepatitis C virus (HCV) on the risk of cirrhosis is still unexplored because a large sample size is required for this investigation. Objective Evaluation of interaction of HBV, HCV and alcohol abuse on the risk of cirrhosis. Design We analysed 12,262 consecutive patients with chronic liver disease of various aetiologies referring to 95 Italian liver units in 2001 or 2014. To evaluate the interaction between alcohol abuse, HBV infection, and HCV infection, patients unexposed to either factors were used as reference category. Adjustment for BMI and age was done by multiple logistic regression analysi…

Genetics and Molecular Biology (all)0301 basic medicineLiver CirrhosisRNA virusesMaleChronic HepatitisCirrhosislcsh:MedicineAlcohol abuseHepacivirusSex FactorChronic liver diseasemedicine.disease_causeBiochemistryGastroenterologyChronic Liver Disease0302 clinical medicineRisk FactorsMedicine and Health Scienceslcsh:SciencePathology and laboratory medicineMultidisciplinaryAlcohol ConsumptionHepatitis C virusLiver DiseasesFatty livervirus diseasesHepatitis CHepatitis BMedical microbiologyMiddle AgedHepatitis BHepatitis CCirrhosisOncologyVirusesCoinfection030211 gastroenterology & hepatologyFemalePathogensResearch ArticleHumanAdultmedicine.medical_specialtyHepatitis B virusAlcohol DrinkingLiver CirrhosiGastroenterology and HepatologyMicrobiologyCarcinomas03 medical and health sciencesSex FactorsInternal medicineGastrointestinal TumorsmedicineHumansNutritionAgedHepatitis B virusBiochemistry Genetics and Molecular Biology (all)Flavivirusesbusiness.industryRisk Factorlcsh:ROrganismsViral pathogensBiology and Life SciencesCancers and NeoplasmsHepatocellular Carcinomamedicine.diseaseVirologydigestive system diseasesHepatitis virusesAdult; Aged; Alcohol Drinking; Female; Hepatitis B; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Risk Factors; Sex Factors; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)DietMicrobial pathogensFatty Liver030104 developmental biologyAgricultural and Biological Sciences (all)lcsh:Qbusiness
researchProduct

Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens

2017

Background Intracellular HCV-RNA reduction is a proposed mechanism of action of direct-acting antivirals (DAAs), alternative to hepatocytes elimination by pegylated-interferon plus ribavirin (PR). We modeled ALT and HCV-RNA kinetics in cirrhotic patients treated with currently-used all-DAA combinations to evaluate their mode of action and cytotoxicity compared with telaprevir (TVR)+PR. Study design Mathematical modeling of ALT and HCV-RNA kinetics was performed in 111 HCV-1 cirrhotic patients, 81 treated with all-DAA regimens and 30 with TVR+PR. Kinetic-models and Cox-analysis were used to assess determinants of ALT-decay and normalization. Results HCV-RNA kinetics was biphasic, reflecting …

Genetics and Molecular Biology (all)SimeprevirMaleHepacivirusHepacivirusPharmacologyBiochemistryStiffness0302 clinical medicineAnimal CellsMedicineAmino Acidslcsh:ScienceAlanineOrganic CompoundsLiver Diseases3. Good healthCirrhosisPhysical SciencesAdministrationInterferon030211 gastroenterology & hepatologyDrug Therapy CombinationCellular TypesOligopeptidesHumanOralMaterials ScienceGastroenterology and HepatologyMicrobiologyAntiviral Agents03 medical and health sciencesDrug TherapyHumansAgedKineticPharmacologyHepaciviruBiochemistry Genetics and Molecular Biology (all)Mathematical Modelinglcsh:RChemical CompoundsBiology and Life SciencesProteinsmedicine.diseasedigestive system diseasesAdministration Oral; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Kinetics; Male; Middle Aged; Oligopeptides; RNA Viral; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)030104 developmental biologyAgricultural and Biological Sciences (all)chemistryAliphatic Amino Acidslcsh:Q0301 basic medicineSofosbuvirlcsh:MedicineAdministration OralMedicine (all); Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Viral Nonstructural ProteinsTelaprevirchemistry.chemical_compoundSimeprevirMedicine and Health SciencesViralMultidisciplinarybiologyAntimicrobialsMedicine (all)Simulation and ModelingDrugsAlanine TransaminaseHepatitis CMiddle AgedAntiviralsHepatitis CChemistryTreatment OutcomeLiverCombinationOligopeptideRNA ViralFemaleAnatomymedicine.drugResearch ArticleSettore MED/17 - Malattie InfettiveGeneral Science & TechnologyMaterial PropertiesResearch and Analysis MethodsMicrobial ControlVirologyRibavirinMechanical PropertiesNS5AAntiviral Agentbusiness.industryRibavirinHCV DAA ALTViral Nonstructural ProteinOrganic ChemistryCell Biologybiology.organism_classificationKineticsAlanine transaminaseAdministration Oral; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Kinetics; Male; Middle Aged; Oligopeptides; RNA Viral; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteinsbiology.proteinHepatocytesRNAInterferonsSofosbuvirbusiness
researchProduct

Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in li…

2008

Introduction. Long-term steroid administration may predispose liver transplant recipients to infectious and metabolic complication. Maintaining effective immunoprophylaxis while minimizing the negative consequences of steroid therapy could be a key factor in improving clinical outcomes.Methods. Six hundred two patients were randomized to receive tacrolimus (TAC) immunosuppression with a single-steroid bolus and two doses of daclizumab (DAC) or mycophenolate mofetil (MMF).Results. The incidence of biopsy-proven acute rejection was 19.7% in the TAC/DAC group and 16.2% in the TAC/ MMF group (ns). Three-month patient and graft survival were similar. Steroid use at month-3 was low at 5.5% in the…

Graft RejectionLiver CirrhosisMaleDaclizumabmedicine.medical_treatment030230 surgeryLiver transplantationGastroenterology0302 clinical medicineDaclizumabAdrenal Cortex HormonesSafety outcomeAntibacterial agentLiver NeoplasmsAntibodies Monoclonal3. Good healthTreatment OutcomeAcute DiseaseCorticosteroid030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleImmunosuppressive Agentsmedicine.drugAdultmedicine.medical_specialtymedicine.drug_classchemical and pharmacologic phenomenaAntibodies Monoclonal HumanizedMycophenolic acidTacrolimusABO Blood-Group System03 medical and health sciencesInternal medicinemedicineHumansTransplantationTacrolimus monotherapybusiness.industryPatient SelectionSteroid-free immunosuppressionMycophenolic AcidSurvival AnalysisTacrolimusSurgeryLiver TransplantationCalcineurinstomatognathic diseasesRegimenImmunoglobulin GbusinessTransplantation
researchProduct

Comparison of results of combined liver-kidney transplantation vs. isolated liver transplantation

2013

Introduction. Combined liver-kidney transplantation (LKT) is the best therapeutic option for patients with end-stage liver and kidney disease. Objectives. To analyze baseline characteristics and clinical outcome of LKT compared to isolated liver transplantation (LT). Material and methods. The study included 16 LKT performed between 1998 and 2006 and 32 LT matched by age, sex, date and indication for transplantation. Demographic, pretransplant, post-transplant and survival variables were analyzed. Results. As planned by the study design, mean age, distribution by sex and indication for LT were similar between groups. The most common indication for LT was HCV- and/or alcohol-induced cirrhosis…

Graft RejectionMaleTime FactorsCirrhosismedicine.medical_treatmentSpecialties of internal medicineKaplan-Meier EstimateLiver transplantationGastroenterologyKidney transplantationchemistry.chemical_compoundMetabolic complicationsRisk FactorsKidney transplantationOutcomeBacterial InfectionsGeneral MedicineMiddle AgedSurvival RateTreatment OutcomeRC581-951CreatinineHepatocellular carcinomaHypertensionFemaleAdultReoperationmedicine.medical_specialtyAdolescentPostoperative HemorrhageEnd Stage Liver DiseaseRenal DialysisDiabetes mellitusInternal medicinemedicineHumansArterial PressureDialysisAgedCreatinineChi-Square DistributionLiver transplantationHepatologyurogenital systembusiness.industrymedicine.diseaseSurgeryTransplantationchemistryCase-Control StudiesKidney Failure ChronicbusinessBiomarkers
researchProduct

Hepatitis C virus re-infection: new perspectives

2006

Hepatitis C virus (HCV) re-infection of the liver graft has been recognized to be one of the most important factors that determines prognosis and outcome after liver transplantation in HCV-positive patients. Graft loss due to recurrent HCV re-cirrhosis and subsequent hepatic decompensation, which is the predominant cause of death among transplant recipients, reflects the prognostic significance of HCV re-infection. Despite better overall outcome after liver transplantation, the prognosis of HCV-infected patients has not improved during the last two decades. Recent data suggest that increased liver donor age and intensified immunosuppression of transplant patients are the most important cont…

Graft RejectionOncologymedicine.medical_specialtyCirrhosismedicine.medical_treatmentHepatitis C virusHepacivirusHepacivirusLiver transplantationmedicine.disease_causechemistry.chemical_compoundRecurrenceInternal medicinemedicineHumansCause of deathTransplantationbiologybusiness.industryRibavirinImmunosuppressionHepatitis C Chronicmedicine.diseasebiology.organism_classificationLiver TransplantationTransplantationchemistryImmunologybusinessClinical Transplantation
researchProduct

Physical frailty in liver transplantation.

2020

In patients with cirrhosis, frailty represents a status of global physical dysfunction associated with a multiplicity of factors, including muscle wasting, undernutrition and malnutrition, and functional impairment. This condition is particularly prevalent among those with advanced cirrhosis, such as liver transplant (LT) candidates. Studies in this vulnerable population have demonstrated that its presence is independently predictive of adverse outcomes both pre- and post-transplantation, and thus that its incorporation into clinical practice could result in improved clinical decision-making, particularly regarding the identification of candidates for physical and nutritional interventions.…

GynecologyLiver Cirrhosismedicine.medical_specialtyCirrosis hepaticaFrailtybusiness.industryClinical Decision-MakingMalnutritionGastroenterologyGeneral MedicineLiver TransplantationmedicineHumansbusinessRevista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva
researchProduct